Grifols

Biopharmaceutical Research and Products

Grifols is a global biopharmaceutical company founded in Barcelona in 1909. It develops, produces, and markets medicines derived from human plasma, other biopharmaceuticals, and solutions for transfusion medicine, diagnostics, and hospitals. Its products are available in more than 110 countries.

Business Areas

• Biopharma: innovative plasma-derived medicines for chronic and rare diseases.
• Diagnostics: diagnostic solutions.
• Bio Supplies: biological supplies.
• Hospital solutions: products and services for hospital settings.

Therapeutic Areas

The company researches and develops treatments in immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases. Its research includes the CHRONOS-PD study on plasma science and Parkinson’s disease.

Global Presence and Corporate Information

Grifols has its institutional headquarters in Barcelona, where a street has been named in honor of Víctor Grífols i Lucas. The company has a global research and development network and operates in Africa, the Americas, Asia, Europe, and Oceania. In 2026, the company reported revenue of €3.6 billion and net income of €227 million through June, as well as progress in Phase 3 clinical trials for its immunoglobulins and Prolastin-C.

Recognition

For three consecutive years, TIME magazine has included Grifols among the world’s best companies. Forbes has named it one of the world’s best employers for two consecutive years.

Contact

Phone: +34 935 712 200 or +34 938 008 000.